GPRC6A and fatty liver disease: This upstream peptide is similar to the pentadecapeptide WLGAPVPYPDPLEPR that is reported to activate GPRC6A in vitro and to improve fatty liver disease and insulin resistance after oral or intraperitoneal administration to a mouse model.37